Trials / Completed
CompletedNCT04753671
QUANTRA® References Range Protocol in Pregnancy and Postpartum
Normal Pregnancy and Postpartum Reference Ranges Intervals for QUANTRA® (STAGO BIOCARE) Hemostasis Point of Care Device
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 31 (actual)
- Sponsor
- University Hospital, Lille · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Postpartum hemorrhage (PPH) remains the leading cause of maternal death. PPH associated coagulopathy varies and their treatments (tranexamic acid, fibrinogen concentrates,plasma, platelets need to be targeted and administrated early. Point of care hemostasis devices are helpful to develop this strategy. Quantra® (STAGO BIOCARE) use an innovative method to detect the clot formation. Pregnancy and non-hemorrhagic postpartum reference ranges are missing. The objective of this study is to establish these norms needed to elaborate thereafter the thresholds to be targeted in PPH conditions.
Conditions
Timeline
- Start date
- 2021-05-05
- Primary completion
- 2022-11-07
- Completion
- 2022-11-07
- First posted
- 2021-02-15
- Last updated
- 2025-12-26
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04753671. Inclusion in this directory is not an endorsement.